🏛️ Verified NIH Record • Updated 2026-06-29

A Virtual Clinical Trial to Examine the Effect of Magnesium Choline Citrate on Cognitive Function and Anxiety in Healthy Adolescents and Adults (NCT07685613)

A Randomized, Triple-blind, Placebo Controlled, Parallel Virtual Clinical Trial to Examine the Effect of Magnesium Choline Citrate on Cognitive Function and Anxiety in Healthy Adolescents and Adults

🟡 Not Yet Recruiting Observational / Diagnostic 📋 Clinical Research Protocol Sponsor: Nutrisol, LLC

🩺 Plain-English Summary (8th-Grade Level)

The goal of this clinical trial is to examine the effect of Magnesium Choline Citrate on cognitive function and anxiety in healthy adolescents and adults. The main questions it aims to answer are: * What is the change in cognitive function, as assessed by the PROMIS Cognitive Function- Short Form 8a (≥18 years old) from baseline to Day 84 between Magnesium Choline Citrate and placebo? * What is the change in cognitive function, as assessed by the Pediatric Cognitive Function - Short Form 7a (8 - 17 years old) from baseline to Day 84 between Magnesium Choline Citrate and placebo? Researchers will compare Magnesium Choline Citrate with placebo to evaluate its effects on cognitive function and anxiety symptoms. Participants will be asked to: * Consume either Magnesium Choline Citrate or placebo for 84 days * Complete questionnaires (PROMIS Cognitive Function- Short Form 8a/Pediatric Cognitive Function - Short Form 7a, and PROMIS Emotional Distress - Anxiety - Short Form 8a/Pediatric Anxiety - Short Form 8a) * Complete a study diary weekly

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (11 items) and avoid the listed exclusions (21 items).

Location: KGK Science Inc. — London, Ontario

Age range: 8 Years

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Individuals who self-report as pregnant, breast feeding, or planning to become pregnant during the study
  • Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational product or placebo ingredients
  • Self-reported ongoing diagnosis of a neuropsychiatric condition and/or cognitive impairment
  • Self-reported ongoing diagnosis with a stress or anxiety disorder
  • Self-reported ongoing and unstable diseases/conditions in the past six months, including:
  • Gastrointestinal diseases
  • Hypertension
  • Type I or type II diabetes
  • Cardiovascular disease
  • Kidney and/or liver diseases
  • Thyroid condition

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

  • KGK Science Inc. — London, Ontario

📞 Contact the Study Coordinator

Phone: (226) 242-4551

Email: elewis@kgkscience.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗